Tracking esophageal cancer changes with genetics and imaging
Part of Cancer, Digestive system clinical trials.
This study uses advanced genetic and imaging tests to monitor how esophageal cancer evolves during treatment. It aims to better understand the disease and guide care for people before and after surgery or on first-line immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 79 years old and in good daily health (able to do light activity).
- You have squamous cell esophageal cancer confirmed by biopsy or strongly suspected if surgery is not possible.
- If you had surgery, you completed standard chemotherapy or radiation before it, and your tumor sample is available.
- If you are starting immunotherapy for advanced cancer, you have not had any previous cancer treatment, and you have a tissue sample (or a recent biopsy slide).
- You agree to share your medical information and attend follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immunotherapy after surgery can help prevent cancer from returning in patients with esophageal squamous cell carcinoma. It is for people who have already received chemotherapy and immunotherapy before surgery and had surgery to remove the cancer, but still had some cancer cells found in the removed tissue.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial compares the current standard treatment (chemotherapy and radiation) with a newer approach that combines chemotherapy and immunotherapy before surgery for esophageal cancer. Participation may help determine if this new combination is more effective for you.
This trial tests a combination of short-course radiation, an immunotherapy drug called tislelizumab, and chemotherapy before surgery for esophageal cancer that has spread to nearby lymph nodes but hasn't spread to distant organs. The goal is to shrink the tumor before surgery and improve outcomes.
This trial tests a treatment plan that combines immunotherapy with chemotherapy before possible endoscopic surgery. It is for people with a specific type of esophageal cancer that has not been treated before and is either potentially removable or not suitable for standard surgery.
This trial tests giving immunotherapy (PD-1 inhibitors) along with local treatments like radiation or surgery at different times for patients whose esophageal cancer has spread to only a few spots. The goal is to see the best timing for these combined treatments.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.